Becampanel (AMP 397) (Synonyms: AMP 397) |
| Catalog No.GC33723 |
Becampanel(AMP 397)(AMP397)은 최초의 경쟁력 있는 AMPA 길항제이자 항간질제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 188696-80-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Becampanel (AMP397) is the first competitive AMPA antagonist and an antiepileptic agent.
Becampanel is negative in a mouse lymphoma tk assay, which includes a 24 h treatment without S9. A weak micronucleus induction in vitro is found at the highest concentrations tested in V79 cells with S9[1].
Becampanel is negative in the following in vivo studies, which includes the maximum tolerated doses of 320 mg/kg in mice and 2000 mg/kg in rats. Becampanel has no genotoxic potential in vivo[1].
[1]. Suter W, et al. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. Mutat Res. 2002 Jul 25;518(2):181-94.
Animal experiment: | The study protocol is in compliance with the corresponding OECD guideline. The test article is dissolved in 0.2 M NaHCO3. The dose-finding experiment with Becampanel shows that treatment of CD-1 mice by oral gavage with 450.5, 500 or 800 mg/kg, twice with an interval of 24 h, leads to strong signs of toxicity such as laboured breathing, ataxia, and strong sedation. At 320 mg/kg, the same symptoms are visible, but with less severity, and no animals die. On the basis of these results, doses of 32, 100 and 320 mg/kg are chosen for this micronucleus test. In the main experiment five male and five female mice are treated as described above and bone marrow is sampled 48 h after the first application. Nucleated cells are removed from the bone marrow samples using cellulose columns. The cells are loaded on poly-l-lysine coated glass slides by cytocentrifugation using a Shandon Cytospin stained with May Grunwald stain (5%) and Giemsa (14%). The slides are automatically evaluated with a LEITZ MIAS image analyser. No statistical analysis is performed since all values in the treated groups are≤the frequency of micronucleated polychromatic erythrocyte in the concurrent vehicle control group. |
References: [1]. Suter W, et al. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. Mutat Res. 2002 Jul 25;518(2):181-94. | |
| Cas No. | 188696-80-2 | SDF | |
| Synonyms | AMP 397 | ||
| Canonical SMILES | O=C1C(NC2=CC([N+]([O-])=O)=CC(CNCP(O)(O)=O)=C2N1)=O | ||
| Formula | C10H11N4O7P | M.Wt | 330.19 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0286 mL | 15.1428 mL | 30.2856 mL |
| 5 mM | 0.6057 mL | 3.0286 mL | 6.0571 mL |
| 10 mM | 0.3029 mL | 1.5143 mL | 3.0286 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *